https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasi...

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side effects.

$120 million industry investment will grow talent and innovation in Virginia's life sciences ecosystem.RICHMOND, Va., Nov. ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application ...

The company is planning to present detailed findings from this trial at a future scientific congress and to submit applications...

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has a...

Deutsche Bank analyst James Shin maintains Merck & Co (NYSE:MRK) with a Hold and raises the price target from $110 to $111.

Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more than 1% by midday in New Y...

Merck's Winrevair drug achieved its primary goal in the Phase 2 CADENCE study for combined post- and pre-capillary pulmonar...